Physician
Oncology
Dr. Sattva S. Neelapu, MD
|
|
Give Review
Sattva Neelapu practices Oncology. Sattva Neelapu is also a published physician. He has 81 publication published. The most recent publication is: Hedgehog inhibitors selectively target cell migration and adhesion of mantle cell lymphoma in bone marrow microenvironment. He accepts all Medicare patients.
Publications
- Hedgehog inhibitors selectively target Cell migration and adhesion of mantle Cell lymphoma in bone marrow microenvironment.
- Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin Lymphoma.
- Cancer immunotherapy: Strategies for personalization and combinatorial approaches.
- Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-Cell lymphoma.
- Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory Lymphoma.
- Detection of classical Hodgkin Lymphoma specific sequence in peripheral blood using a next-generation sequencing approach.
- Safety and activity of lenalidomide and rituximab in untreated indolent Lymphoma: an open-label, phase 2 trial.
- Rush hour traffic: directing T Cells to tumor.
- Pegylated Liposomal Doxorubicin Replacing Conventional Doxorubicin in Standard R-CHOP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma: An Open Lab...
- (90) Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-Cell lymphomas, including bulky disease.
- Double hit lymphoma: the MD Anderson Cancer Center clinical experience.
- Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-Cell function in follicular lymphoma.
- FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-Cell lymphoma.
- Anti-PD-1 antibodies for the treatment of B-Cell lymphoma: Importance of PD-1(+) T-Cell subsets.
- Transcription factor achaete-scute homologue 2 initiates follicular T-helper-Cell development.
- Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular Lymphoma: a single group, open-label, phase 2 trial.
- The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin Lymphoma.
- Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse larg...
- Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma.
- Detection of circulating tumour DNA in patients with aggressive B-Cell non-Hodgkin lymphoma.
- Immune evasion of mantle Cell lymphoma: expression of B7-H1 leads to inhibited T-Cell response to and killing of tumor Cells.
- Nonstereotyped lymphoma B Cell receptors recognize vimentin as a shared autoantigen.
- Cross Talk between Follicular Th Cells and Tumor Cells in Human Follicular Lymphoma Promotes Immune Evasion in the Tumor Microenvironment.
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large Cell, follicular and transformed lymphoma: a phase II clinical trial.
- Phase I Study of a Novel Oral Janus Kinase 2 Inhibitor, SB1518, in Patients With Relapsed Lymphoma: Evidence of Clinical and Biologic Activity in Multiple Lymphoma Sub...
- Transcription and translation are primary targets of Pim kinase inhibitor, SGI-1776, in mantle Cell lymphoma.
- Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/R...
- Hodgkin Lymphoma Untreated for Six Years Presenting with Tracheoesophageal Fistula.
- Essential role of TAK1 in regulating mantle Cell lymphoma survival.
- Neoantigen and tumor antigen-specific immunity transferred from immunized donors is detectable early after allogeneic transplantation in Myeloma patients.
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-Cell lymphoma: a phase 1/2 clinical trial.
- Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular Lymphoma: 12-year results.
- MicroRNA profiling of follicular lymphoma identifies microRNAs related to Cell proliferation and tumor response.
- Idiotype Vaccination As Consolidation Therapy: Time for Integration Into Standard of Care for Follicular Lymphoma?
- Targeting human B-Cell malignancies through Ig light chain specific cytotoxic T lymphocytes.
- Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma.
- Follicular regulatory T Cells expressing Foxp3 and Bcl-6 suppress germinal center reactions.
- 8-Aminoadenosine inhibits Akt/mTOR and Erk signaling in mantle Cell lymphoma.
- Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T Cell-, and not B Cell-, dependent antilymphoma immunity.
- Vaccination strategies in follicular Lymphoma.
- Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patie...
- Eight-year experience with allogeneic stem Cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide...
- A novel proteoliposomal vaccine induces antitumor immunity against follicular Lymphoma.
- A novel proteoliposomal vaccine elicits potent antitumor immunity in mice.
- Vaccine therapy for B-Cell lymphomas: next-generation strategies.
- Vaccine-induced tumor-specific immunity despite severe B-Cell depletion in mantle Cell lymphoma.
- Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular Lymphoma in first complete remission: protocol summary and...
- Human autologous tumor-specific T-Cell responses induced by liposomal delivery of a lymphoma antigen.
- Chemokine receptor-mediated deLivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo.
- A modified human ELISPOT assay to detect specific responses to primary tumor Cell targets.
- Adoptive immunotherapy with antigen-specific T Cells in myeloma: a model of tumor-specific donor lymphocyte infusion.
- ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies.
- Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma.
- A pilot study of CTLA-4 blockade after Cancer vaccine failure in patients with advanced malignancy.
- Leptomeningeal Carcinomatosis in metastatic prostate cancer.
- Phase II trial of the combination of denileukin diftitox and rituximab for relapsed/refractory B-Cell non-Hodgkin lymphoma.
- Prophylactic anti-tumor effects in a B Cell lymphoma model with DNA vaccines delivered on polyethylenimine (PEI) functionalized PLGA microparticles.
- Cloning of B Cell lymphoma-associated antigens using modified phage-displayed expression cDNA library and immunized patient sera.
- Mocetinostat for relapsed classical Hodgkin's Lymphoma: an open-label, single-arm, phase 2 trial.
- HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle Cell lymphoma.
- Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle Cell lymphoma.
- Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin Lymphoma.
- Active vaccination with Dickkopf-1 induces protective and therapeutic antitumor immunity in murine multiple Myeloma.
- EPOCH-F: a novel salvage regimen for multiple Myeloma before reduced-intensity allogeneic hematopoietic SCT.
- Identification of human idiotype-specific T Cells in lymphoma and myeloma.
- Expression of histone deacetylases in Lymphoma: implication for the development of selective inhibitors.
- A novel strategy for rapid and efficient isolation of human tumor-specific CD4(+) and CD8(+) T-Cell clones.
- Survivin DNA vaccine generated specific antitumor effects in pancreatic Carcinoma and lymphoma mouse models.
- Prospective trial of targeted radioimmunotherapy with Y-90 ibritumomab tiuxetan (Zevalin) for front-line treatment of early-stage extranodal indolent ocular adnexal ly...
- Developing idiotype vaccines for Lymphoma: from preclinical studies to phase III clinical trials.
- ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-Cell lymphoma.
- Induction of TLR4-dependent CD8+ T Cell immunity by murine β-defensin2 fusion protein vaccines.
- Generation of an immune microenvironment as a novel mechanism for myotoxins to potentiate genetic vaccines.
- Prospective isolation of clonogenic mantle Cell lymphoma-initiating Cells.
- Tumor antigen immunization of sibling stem Cell transplant donors in multiple myeloma.
- Therapeutic vaccine for Lymphoma.
- Idiotypic vaccination for B-Cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
- Detection of keyhole limpet hemocyanin (KLH)-specific immune responses by intraCellular cytokine assay in patients vaccinated with idiotype-KLH vaccine.
- BiovaxID: a personalized therapeutic Cancer vaccine for non-Hodgkin''s lymphoma.
- Therapeutic lymphoma vaccines: importance of T-Cell immunity.
Schools
Jawaharlal Institute of PostGraduate Medical Education Madras University
Coney Island Hospital
Procedures Preformed
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Anemia
- Basal Cell Carcinoma
- Bladder Cancer
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Education
-
National Institutes of Health Clinical Center -
Jawaharlal Institute of Postgraduate Medical Education and Research
Hospital
-
University of Texas M.D. Anderson Cancer Center
Drug Facts
| NPI NUMBER | 1386736304 | |
| NPPES Provider LastName | NEELAPU | |
| NPPES Provider FirstName | SATTVA | |
| NPPES Provider ZIPCode | 770304009 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 426.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1386736304 |
| Last Name Of The Provider | NEELAPU |
| First Name Of The Provider | SATTVA |
| View All |
Similar Doctors
|
|
Dr. Marc S. Hoffmann, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeong H. Oh, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Craig A. Kovitz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Merrill S. Kies, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Hagop M. Kantarjian, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
Dr. Harry R. Price, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria A. Zarzour, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicholas Mitsiades, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Donna S. Zhukovsky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Patrick Hwu, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Guillermo Garcia-Manero, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Miloslav I. Beran, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Antonio C. Buzaid, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. An N. Hoang, MD |
|
|
Dr. Naoto Ueno, MD
This Doctor is OpenDoctor Recommended.
|